Rag2-KO/hVEGFR2
系統名
C57BL/6Smoc-Kdrtm2(hKDR)Rag2em1Smoc
SMOC番号
NM-HU-200280
維持形態
Embryo cryopreservation
説明
表現型データ
Fig1. In vivo anti-tumor response of Cyramza and Avastin in the treatment of gastric cancer PDX model(GA2419)in the immunodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)
(A)Breeding scheme for development of Rag2-KO/hKDR mice; (B) Tumor growth curves upon treatment of Cyramza and Avastin; (C) Body weight change upon treatment.
Fig2. In vivo anti-tumor response of Cyramza in thetreatment of liver cancer PDX model(LI0612)in the im-munodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)
(A)Tumor blood vesselstaining via anti-human VEGFR2 IHC; (B) Tumor growth curves upon Cyramza treatment; (C)Body weight change upon treatment.
あなたも好きかも
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
詳細At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
詳細